Sobrerol
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Sobrerol is a mucolytic indicated in patients with chronic respiratory diseases.
- Generic Name
- Sobrerol
- DrugBank Accession Number
- DB13315
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 170.252
Monoisotopic: 170.13067982 - Chemical Formula
- C10H18O2
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination for symptomatic treatment of Febrile respiratory illness Combination Product in combination with: Acetaminophen (DB00316) ••• ••• •••••••••••• •••••• •••••• For therapy Respiratory disorders •••••••••••• ••••• •••••••••• •••••••• For therapy Respiratory disorders •••••••••••• •••••••• ••• ••••••••• •••••• ••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image MUCOFLUX 100mg capsules Capsule Oral MYLAN HEALTHCARE SDN. BHD. 2020-09-08 Not applicable Malaysia MUCOFLUX 80mg/10ml syrup Syrup Oral MYLAN HEALTHCARE SDN. BHD. 2020-09-08 Not applicable Malaysia มิวโคฟลักซ์ Capsule 100 mg Oral บริษัท เมด้า ฟาม่าร์ (ประเทศไทย) จำกัด 2012-01-25 Not applicable Thailand มิวโคฟลักซ์ Syrup 40 mg/5ml Oral บริษัท เมด้า ฟาม่าร์ (ประเทศไทย) จำกัด 2012-01-25 Not applicable Thailand
Categories
- ATC Codes
- R05CB07 — Sobrerol
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as menthane monoterpenoids. These are monoterpenoids with a structure based on the o-, m-, or p-menthane backbone. P-menthane consists of the cyclohexane ring with a methyl group and a (2-methyl)-propyl group at the 1 and 4 ring position, respectively. The o- and m- menthanes are much rarer, and presumably arise by alkyl migration of p-menthanes.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Monoterpenoids
- Direct Parent
- Menthane monoterpenoids
- Alternative Parents
- Monocyclic monoterpenoids / Tertiary alcohols / Secondary alcohols / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic homomonocyclic compound / Hydrocarbon derivative / Monocyclic monoterpenoid / Organic oxygen compound / Organooxygen compound / P-menthane monoterpenoid / Secondary alcohol / Tertiary alcohol
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- AI0NX02O35
- CAS number
- 42370-41-2
- InChI Key
- OMDMTHRBGUBUCO-BDAKNGLRSA-N
- InChI
- InChI=1S/C10H18O2/c1-7-4-5-8(6-9(7)11)10(2,3)12/h4,8-9,11-12H,5-6H2,1-3H3/t8-,9+/m1/s1
- IUPAC Name
- (1S,5R)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol
- SMILES
- CC1=CC[C@H](C[C@@H]1O)C(C)(C)O
References
- General References
- External Links
- ChemSpider
- 746841
- 36669
- ChEMBL
- CHEMBL2374961
- ZINC
- ZINC000000407097
- Wikipedia
- Sobrerol
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral Granule Granule 300 MG Injection, solution Intramuscular Solution / drops Oral Spray Respiratory (inhalation) 40 MG/3ML Suppository Rectal 100 MG Suppository Rectal 20 MG Suppository Rectal 200 MG Syrup Oral Granule, for solution Oral 300 MG Suppository Rectal Syrup Oral Tablet Oral Capsule Oral 100 mg Syrup Oral 40 mg/5ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 26.0 mg/mL ALOGPS logP 1.54 ALOGPS logP 0.94 Chemaxon logS -0.82 ALOGPS pKa (Strongest Acidic) 14.48 Chemaxon pKa (Strongest Basic) -2.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 40.46 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 49.98 m3·mol-1 Chemaxon Polarizability 19.58 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0zfu-9300000000-df2133dd98164dcd6984 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-1900000000-949debf034a40ad213d9 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0f89-0900000000-db60ed94784ba582e165 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0900000000-4a1b800096b1f800929e Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-9300000000-06d284affa10c9871e19 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-000f-9500000000-0f7ea1d1b37818a0bd30 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0k96-9100000000-c89e3ada8b454d9f3161 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 141.0360316 predictedDarkChem Lite v0.1.0 [M-H]- 143.35823 predictedDeepCCS 1.0 (2019) [M+H]+ 142.7818316 predictedDarkChem Lite v0.1.0 [M+H]+ 145.7538 predictedDeepCCS 1.0 (2019) [M+Na]+ 141.0403316 predictedDarkChem Lite v0.1.0 [M+Na]+ 151.6663 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:39 / Updated at June 02, 2021 20:04